Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 15/20 | 0.40 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143005 | 0.83 | NR4A2 (0.60) | NR4A2DYRK1ATDO2 | |
| SCHEMBL19991853 | 0.81 | NR4A2 (0.42) | NR4A2TDO2 | |
| SCHEMBL19991846 | 0.76 | IMPDH2 (0.46) | NR4A2DYRK1A | |
| SCHEMBL4459584 | 0.75 | MPO (0.33) | NR4A2 | |
| SCHEMBL695280 | 0.73 | TRPA1 (0.52) | DYRK1A | |
| SCHEMBL694834 | 0.71 | NR1I2 (0.40) | ALOX5 | |
| SCHEMBL699272 | 0.70 | NR4A2 (0.60) | NR4A2TDO2 | |
| SCHEMBL2428032 | 0.69 | PTGS2 (0.36) | — | |
| SCHEMBL2431965 | 0.69 | AKR1C3 (0.43) | — | |
| SCHEMBL694000 | 0.69 | CYP1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | MGLL, LIPA, PNLIP | NR4A2 4005/4885DYRK1A 4269/4885TDO2 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.